EcoDrugPlus

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSBBBG00000013293
Gene Symbol: NR1H3
3 Cross references
392 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSBBBG00000003455
Gene Symbol: NR1H4
3 Cross references
388 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSBBBG00000010266
Gene Symbol: NR3C1
3 Cross references
280 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSBBBG00000002997
Gene Symbol: NR3C2
3 Cross references
214 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSBBBG00000017827
Gene Symbol: NOD2
3 Cross references
167 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSBBBG00000001678
Gene Symbol: OPRD1
1 Cross references
254 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSBBBG00000017852
Gene Symbol: OPRK1
3 Cross references
264 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSBBBG00000012004
Gene Symbol: OPRM1
3 Cross references
215 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSBBBG00000004623
Gene Symbol: OPRL1
3 Cross references
202 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSBBBG00000014600
Gene Symbol: OXTR
3 Cross references
265 Possible Orthologues:

Pancreatic Lipase

Ensembl ID : ENSBBBG00000009937
Gene Symbol: PNLIP
3 Cross references
301 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSBBBG00000015265
Gene Symbol: PTH1R
3 Cross references
199 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).